Halozyme: European Approval Of Roche's MabThera SC For Non-Hodgkin ... NASDAQ (RTTNews.com) - Halozyme Therapeutics Inc ( HALO ) said Friday the European Commission has approved Roche's ( RHHBY ) new subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large ... |
